Nationwide Fund Advisors Has $938000 Holdings in Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

January 14th, 20187:52 am @

0


Nationwide Fund Advisors lifted its position in shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities Exchange Commission. The fund owned 65,480 shares of the specialty pharmaceutical company’s stock after buying an additional 13,080 shares during the period. Nationwide Fund Advisors’ holdings in Valeant Pharmaceuticals Intl were worth $938,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in VRX. Eaton Vance Management boosted its position in Valeant Pharmaceuticals Intl by 1.2% during the 2nd quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 500 shares during the period. Commonwealth Bank of Australia boosted its position in Valeant Pharmaceuticals Intl by 0.7% during the 2nd quarter. Commonwealth Bank of Australia now owns 108,806 shares of the specialty pharmaceutical company’s stock worth $1,887,000 after purchasing an additional 800 shares during the period. GSA Capital Partners LLP boosted its position in Valeant Pharmaceuticals Intl by 10.5% during the 2nd quarter. GSA Capital Partners LLP now owns 21,651 shares of the specialty pharmaceutical company’s stock worth $375,000 after purchasing an additional 2,051 shares during the period. Moors Cabot Inc. boosted its position in Valeant Pharmaceuticals Intl by 32.3% during the 2nd quarter. Moors Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after purchasing an additional 3,725 shares during the period. Finally, Intact Investment Management Inc. boosted its position in Valeant Pharmaceuticals Intl by 3.2% during the 2nd quarter. Intact Investment Management Inc. now owns 156,100 shares of the specialty pharmaceutical company’s stock worth $3,501,000 after purchasing an additional 4,900 shares during the period. Institutional investors and hedge funds own 49.45% of the company’s stock.

VRX has been the subject of a number of research reports. Cantor Fitzgerald set a $23.00 price target on shares of Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Piper Jaffray Companies reissued a “sell” rating and issued a $12.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Friday, November 10th. Vetr raised shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “strong-buy” rating and set a $19.72 price objective for the company in a research report on Tuesday, December 5th. TD Securities raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Tuesday, November 7th. Finally, ValuEngine raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. Six analysts have rated the stock with a sell rating, ten have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Valeant Pharmaceuticals Intl presently has a consensus rating of “Hold” and a consensus price target of $18.20.

In related news, Director John Paulson bought 344,216 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were acquired at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the purchase, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 5.87% of the company’s stock.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) opened at $23.84 on Friday. The stock has a market cap of $8,310.00, a PE ratio of 6.11, a PEG ratio of 0.72 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. Valeant Pharmaceuticals Intl Inc has a 12 month low of $8.31 and a 12 month high of $24.43.

ILLEGAL ACTIVITY NOTICE: This report was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and reposted in violation of US international trademark copyright legislation. The original version of this report can be accessed at https://stocknewstimes.com/2018/01/14/valeant-pharmaceuticals-intl-inc-vrx-position-lifted-by-nationwide-fund-advisors.html.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).




Receive News Ratings for Valeant Pharmaceuticals Intl Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com’s FREE daily email newsletter.

Article source: https://stocknewstimes.com/2018/01/14/valeant-pharmaceuticals-intl-inc-vrx-position-lifted-by-nationwide-fund-advisors.html